GlassScriptPhysician profile
Damian Roussel
NPI 1659436509
$7,010.16
in general payments reported to CMS, 2019-2025
13 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 78% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.14 · 2020: $1,055 · 2021: $178 · 2022: $55.90 · 2023: $1,532 · 2024: $2,639 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Travel and Lodging: $2,078 · Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $2,077.75 |
| Food and Beverage | $1,507.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $6,158.02 | 2020-2025 | |
| Bone Support INC. | $177.71 | 2021 | |
| Paragon 28, INC. | $135.80 | 2025 | Portfolio |
| Smith+Nephew, INC. | $130.11 | 2023-2024 | Stravix Pl, Collagenase Santyl |
| Supreme Orthopedic Systems, LLC | $117.52 | 2023 | |
| Ossio INC | $66.05 | 2022-2023 | |
| Bioventus LLC | $64.56 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Amgen INC. | $52.15 | 2019-2024 | Krystexxa |
| Biocomposites INC | $32.16 | 2025 | Stimulan |
| Pacira Therapeutics, INC. | $24.86 | 2019-2020 | |
| Ibsa Pharma INC. | $21.18 | 2023 | Licart, Tirosint |
| Curonix LLC | $18.55 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Zimmer Biomet Holdings, INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damian Roussel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.